<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width,initial-scale=1" />
<title>Antibiotic & Infection Guide — Complete</title>
<link rel="icon" href="mutant-icon.png" type="image/png">
<style>
  :root{
    --nav-w:300px;
    --header-h:64px;
    --blue:#004080;
    --muted:#f6f8fb;
    --card:#ffffff;
  }
  html{scroll-behavior:smooth}
  html,body{height:100%;margin:0;font-family:Inter,Arial,Helvetica,sans-serif;background:#fbfcfe;color:#1f2937}
  /* Layout */
  header{
    position:fixed;
    left:var(--nav-w);
    right:0;
    top:0;
    height:var(--header-h);
    background:var(--blue);
    color:#fff;
    display:flex;
    align-items:center;
    gap:12px;
    padding:0 16px;
    z-index:1200;
  }
  header img{height:44px;width:44px;object-fit:contain}
  header h1{font-size:1.05rem;margin:0;font-weight:600}
  header .search { margin-left:auto; width:420px; max-width:40vw; }
  header .search input{width:100%;padding:8px;border-radius:8px;border:0;font-size:0.95rem}

  nav#sidebar{
    position:fixed;
    top:0;
    left:0;
    width:var(--nav-w);
    height:100vh;
    background:var(--muted);
    border-right:1px solid #e2e8f0;
    padding:8px 12px;
    box-sizing:border-box;
    overflow:auto;
  }
  #sidebar .title{padding:6px 8px;font-weight:700;color:var(--blue);font-size:1rem}
  #sidebar .search-small{padding:8px}
  #sidebar input[type="text"]{width:100%;padding:8px;border-radius:8px;border:1px solid #e6eef8}

  #sidebar ul{list-style:none;padding:6px;margin:0}
  #sidebar li{margin:6px 0}
  #sidebar a{display:block;padding:8px 10px;color:#0b2545;text-decoration:none;border-radius:6px}
  #sidebar a:hover{background:#e8f1ff}

  main{
    margin-left:var(--nav-w);
    padding:calc(var(--header-h) + 18px) 22px 40px 22px;
    min-height:100vh;
    box-sizing:border-box;
  }

  section{margin-bottom:20px; scroll-margin-top: calc(var(--header-h) + 12px);}
  h2{color:var(--blue); margin:0 0 10px 0}
  .muted{color:#475569;font-size:0.95rem}
  p, li {color:#0b2338;line-height:1.4}

  /* Collapsible */
  .collapsible{
    background:#eef6ff;
    border:1px solid #d7eafc;
    color:var(--blue);
    padding:10px 12px;
    width:100%;
    text-align:left;
    cursor:pointer;
    border-radius:8px;
    font-weight:700;
    margin-top:12px;
    box-sizing:border-box;
  }
  .collapsible:after{content:'+';float:right;font-weight:700}
  .collapsible.active{background:#e3f0ff}
  .collapsible.active:after{content:'−'}
  .panel{
    display:none;
    padding:12px;
    margin-top:8px;
    background:var(--card);
    border-radius:8px;
    border:1px solid #eef2f6;
  }

  table{width:100%;border-collapse:collapse;margin-top:8px}
  th,td{border:1px solid #e6edf6;padding:8px;text-align:left;font-size:14px}
  th{background:#eaf4ff;color:#023e73;font-weight:700}

  .calculator{border:1px solid #e6edf6;padding:12px;border-radius:8px;background:#fff;margin-top:10px}
  .small{font-size:0.92rem;color:#475569}
  .badge{display:inline-block;padding:4px 8px;border-radius:16px;background:#fff;border:1px solid #e6eef8;font-size:12px;margin-right:6px}

  @media (max-width:980px){
    header{left:0}
    nav#sidebar{position:relative;width:100%;height:auto;border-right:none;border-bottom:1px solid #e6edf6;padding-bottom:12px}
    main{margin-left:0;padding-top:calc(var(--header-h) + 10px)}
  }
</style>
</head>
<body>

<nav id="sidebar" aria-label="Main navigation">
  <div class="title">Antimicrobial Guide</div>

  <div class="search-small">
    <input type="text" id="sidebarSearch" placeholder="Quick search (pathogen / drug / syndrome)" />
  </div>

  <ul>
    <li><a href="#homepage">Home — ID Approach</a></li>
    <li><a href="#empiric-therapy">Empiric Therapy</a></li>
    <li><a href="#anatomic-infections">Infections by Site</a></li>
    <li><a href="#high-yield-syndromes">High-Yield Syndromes</a></li>
    <li><a href="#sepsis">Sepsis</a></li>
    <li><a href="#pathogen-guidance">Pathogen Guidance</a></li>
    <li><a href="#pathogen-overview">Pathogen Overview</a></li>
    <li><a href="#antibiotic-classes">Antibiotic Classes</a></li>
    <li><a href="#fungal-infections">Fungal Infections</a></li>
    <li><a href="#viral-infections">Viral Infections</a></li>
    <li><a href="#tickborne-infections">Tickborne Infections</a></li>
    <li><a href="#viral-encephalopathies">Viral Encephalopathies</a></li>
    <li><a href="#calculators">Calculators</a></li>
    <li><a href="#references">References</a></li>
  </ul>

  <div style="padding:12px;color:#334155;font-size:13px">Tip: use the top search for full-text filtering across all sections.</div>
</nav>

<header role="banner">
  <img src="mutant-icon.png" alt="logo" onerror="this.style.display='none'">
  <h1>Antibiotic & Infection Guide <span style="font-size: 0.6em; color: #ff6b6b; font-weight: 600;">BUILD #1</span></h1>
  <div class="search">
    <input id="globalSearch" type="text" placeholder="Search everything — pathogen, drug, syndrome..." />
  </div>
</header>

<main id="main">

<!-- HOME -->
<section id="homepage" aria-labelledby="home-heading">
  <h2 id="home-heading">Home — Basic ID Approach</h2>
  <p class="muted">Concise inpatient approach: history, source identification, empiric therapy, source control, stewardship.</p>
  <ul>
    <li>History: travel, exposures (ticks, animals), recent healthcare/antibiotics, devices.</li>
    <li>Exam: targeted to suspected source; document entry points, devices, neurologic status.</li>
    <li>Diagnostics: obtain blood cultures (2 sets), urine, wound or respiratory cultures before antibiotics when possible.</li>
    <li>Empiric therapy: cover likely pathogens given site, severity, and local antibiogram; reassess at 48–72 hrs.</li>
    <li>Source control: drain abscess, remove infected devices, debride necrotic tissue — essential.</li>
  </ul>

  <h3>Clinical pearls</h3>
  <ul>
    <li>Sepsis: give broad-spectrum antibiotics within 1 hour of recognition; fluids and source control.</li>
    <li>Neutropenic fever: immediate anti-pseudomonal IV therapy.</li>
    <li>Always check renal function before dosing; many agents require adjustment.</li>
  </ul>
</section>

<!-- EMPIRIC THERAPY -->
<section id="empiric-therapy">
  <h2>Empiric Therapy</h2>

  <button class="collapsible">Gram-Positive Cocci (common regimens)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism/Group</th><th>Empiric</th><th>Dose / Route</th><th>Notes / Duration</th></tr></thead>
      <tbody>
        <tr><td>MSSA</td><td>Nafcillin / Oxacillin</td><td>Nafcillin 2 g IV q4h</td><td>7–14 d; longer for endocarditis/osteomyelitis</td></tr>
        <tr><td>MRSA</td><td>Vancomycin</td><td>15 mg/kg IV q12h (AUC/CrCl adjust)</td><td>Monitor levels; 7–21 d</td></tr>
        <tr><td>Streptococci</td><td>Penicillin G / Ceftriaxone</td><td>Pen G 4 MU IV q4h; Ceftriaxone 2 g IV q24h</td><td>10–14 d (site dependent)</td></tr>
        <tr><td>Enterococcus spp.</td><td>Ampicillin ± Gentamicin (synergy)</td><td>Ampicillin 2 g IV q4h</td><td>UTI shorter; endocarditis 4–6 weeks</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Gram-Negative Rods (common regimens)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Group</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Enterobacteriaceae (E. coli, Klebsiella)</td><td>Ceftriaxone / Cefepime / Piperacillin-tazobactam</td><td>Ceftriaxone 1–2 g IV q24h; Cefepime 2 g IV q8h; Pip-tazo 4.5 g IV q6–8h</td><td>Consider carbapenem for ESBL</td></tr>
        <tr><td>Pseudomonas</td><td>Cefepime / Piperacillin-tazobactam / Meropenem</td><td>Cefepime 2 g IV q8h; Meropenem 1 g IV q8h</td><td>Consider combination therapy if critically ill</td></tr>
        <tr><td>Burkholderia</td><td>Ceftazidime ± TMP-SMX</td><td>Ceftazidime 2 g IV q8h</td><td>CF isolates often resistant; tailor to suscept</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Anaerobes / Mixed</button>
  <div class="panel">
    <table>
      <thead><tr><th>Group</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Bacteroides / Prevotella</td><td>Pip-tazo or Carbapenem or Metronidazole combo</td><td>Metronidazole 500 mg IV q8h</td><td>Source control critical in IAIs</td></tr>
        <tr><td>Clostridioides difficile</td><td>Oral Vancomycin or Fidaxomicin</td><td>Vancomycin 125–500 mg PO q6h</td><td>Follow current guideline durations</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Intracellular / Atypical</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Legionella</td><td>Levofloxacin or Azithromycin</td><td>Levo 750 mg IV/PO q24h</td><td>Consider in severe CAP</td></tr>
        <tr><td>Chlamydia / Mycoplasma</td><td>Doxycycline</td><td>Doxy 100 mg PO/IV q12h</td><td>Atypical coverage for CAP</td></tr>
        <tr><td>Nocardia</td><td>TMP-SMX (high-dose)</td><td>TMP 15 mg/kg/day IV divided q6–8h</td><td>Long courses; CNS requires higher dose</td></tr>
      </tbody>
    </table>
  </div>
</section>

<!-- ANATOMIC -->
<section id="anatomic-infections">
  <h2>Infections by Anatomic Site</h2>

  <button class="collapsible">Head & Neck</button>
  <div class="panel">
    <ul>
      <li>Sinusitis (bacterial): Amoxicillin-clavulanate 875/125 mg PO BID ×5–7 days (adult outpatient).</li>
      <li>Mastoiditis: Ceftriaxone 2 g IV q24h; ENT consult for drainage; 10–14 days.</li>
      <li>Otitis media: Amoxicillin 500 mg PO q8h ×5–7 days (adjust for pediatrics).</li>
    </ul>
  </div>

  <button class="collapsible">Respiratory</button>
  <div class="panel">
    <ul>
      <li>CAP (inpatient non-ICU): Ceftriaxone 2 g IV q24h + Azithro 500 mg IV/PO day1 then 250 mg daily ×5–7 d.</li>
      <li>HAP/VAP: Anti-pseudomonal β-lactam ± MRSA agent; 7 days if good response.</li>
      <li>Aspiration pneumonia: cover anaerobes (ampicillin-sulbactam or pip-tazo).</li>
    </ul>
  </div>

  <button class="collapsible">Urinary Tract</button>
  <div class="panel">
    <ul>
      <li>Uncomplicated cystitis: Nitrofurantoin 100 mg PO BID ×5 days (if susceptible).</li>
      <li>Pyelonephritis (inpatient): Ceftriaxone 1–2 g IV q24h or Pip-tazo 4.5 g IV q6–8h; 7–14 days depending on severity.</li>
      <li>Catheter-associated UTI: Remove/replace catheter and treat per culture.</li>
    </ul>
  </div>

  <button class="collapsible">Intra-abdominal</button>
  <div class="panel">
    <ul>
      <li>Complicated IAI: Pip-tazo 4.5 g IV q6–8h or meropenem 1 g IV q8h; drainage of abscesses; 4–14 days depending on source control.</li>
      <li>Appendicitis prophylaxis: Single pre-op cefazolin 2 g IV (add metronidazole if contamination).</li>
    </ul>
  </div>

  <button class="collapsible">Skin & Soft Tissue</button>
  <div class="panel">
    <ul>
      <li>Non-purulent cellulitis: Cefazolin 1–2 g IV q8h (switch to oral cephalexin when improving) — 5–7 days.</li>
      <li>Purulent SSTI: I&D; TMP-SMX or doxycycline if MRSA suspected.</li>
      <li>Necrotizing fasciitis: Broad-spectrum (vancomycin + pip-tazo or carbapenem) + urgent surgical debridement.</li>
    </ul>
  </div>

  <button class="collapsible">Bone & Joint</button>
  <div class="panel">
    <ul>
      <li>Osteomyelitis: Empiric vancomycin ± ceftriaxone pending cultures; 4–6+ weeks therapy guided by ID.</li>
      <li>Septic arthritis: Drainage + empiric vancomycin ± GN coverage; 2–4 weeks therapy.</li>
    </ul>
  </div>
</section>

<!-- HIGH-YIELD SYNDROMES -->
<section id="high-yield-syndromes">
  <h2>High-Yield Syndromes</h2>
  <p class="muted">Detailed management for common hospitalist infectious disease scenarios.</p>

  <button class="collapsible">Infective Endocarditis</button>
  <div class="panel">
    <h4>Modified Duke Criteria (2023 ESC Update)</h4>
    <p><strong>Definite IE:</strong> 2 major, OR 1 major + 3 minor, OR 5 minor criteria</p>
    <p><strong>Major Criteria:</strong></p>
    <ul>
      <li><strong>Blood cultures:</strong> Typical organisms (S. aureus, viridans strep, S. gallolyticus, HACEK, Enterococcus) from 2 separate cultures; OR persistently positive cultures 12h apart; OR ≥3 positive cultures over >1h</li>
      <li><strong>Imaging:</strong> Vegetation, abscess, pseudoaneurysm, dehiscence, or new valve regurgitation on echo; OR abnormal activity on 18F-FDG PET/CT (prosthetic) or cardiac CT showing abscess/pseudoaneurysm</li>
    </ul>
    <p><strong>Minor Criteria:</strong></p>
    <ul>
      <li>Predisposition (IVDU, prosthetic valve, prior IE, structural heart disease)</li>
      <li>Fever ≥38°C</li>
      <li>Vascular phenomena (emboli, mycotic aneurysm, Janeway lesions, conjunctival hemorrhage)</li>
      <li>Immunologic phenomena (Osler nodes, Roth spots, glomerulonephritis, positive RF)</li>
      <li>Microbiologic evidence not meeting major criteria</li>
    </ul>

    <h4>Empiric Therapy (Before Culture Results)</h4>
    <table>
      <tr><th>Scenario</th><th>Regimen</th><th>Notes</th></tr>
      <tr><td>Native valve, community-acquired</td><td>Vancomycin + Ceftriaxone</td><td>Covers MSSA, MRSA, strep, enterococcus</td></tr>
      <tr><td>Native valve, IVDU</td><td>Vancomycin + Ceftriaxone</td><td>High MRSA prevalence; add gentamicin if critically ill</td></tr>
      <tr><td>Prosthetic valve (early <1yr)</td><td>Vancomycin + Gentamicin + Rifampin + Cefepime</td><td>Cover staph, GNR, enterococcus</td></tr>
      <tr><td>Prosthetic valve (late >1yr)</td><td>Vancomycin + Ceftriaxone</td><td>Similar to native valve</td></tr>
    </table>

    <h4>Duration by Organism & Valve</h4>
    <table>
      <tr><th>Organism</th><th>Native Valve</th><th>Prosthetic Valve</th></tr>
      <tr><td>Streptococci (MIC ≤0.12)</td><td>4 weeks (2 wks if + gent)</td><td>6 weeks</td></tr>
      <tr><td>Enterococcus</td><td>4-6 weeks (+ gent synergy)</td><td>6 weeks minimum</td></tr>
      <tr><td>Staphylococcus (MSSA)</td><td>6 weeks</td><td>≥6 weeks + rifampin + gent × 2wks</td></tr>
      <tr><td>Staphylococcus (MRSA)</td><td>6 weeks vanc</td><td>≥6 weeks + rifampin + gent × 2wks</td></tr>
      <tr><td>HACEK</td><td>4 weeks</td><td>6 weeks</td></tr>
    </table>

    <h4>Surgical Indications</h4>
    <ul>
      <li><strong>Emergent (within 24h):</strong> Refractory pulmonary edema, cardiogenic shock from severe AI/MR</li>
      <li><strong>Urgent (within days):</strong> Uncontrolled infection despite abx, abscess, enlarging vegetation, persistent bacteremia >7d, fungal IE</li>
      <li><strong>Elective:</strong> Large vegetation >10mm with embolic event, severe valve dysfunction once stabilized</li>
    </ul>
  </div>

  <button class="collapsible">Bacterial Meningitis</button>
  <div class="panel">
    <h4>Empiric Therapy by Age/Risk</h4>
    <table>
      <tr><th>Population</th><th>Likely Pathogens</th><th>Empiric Regimen</th></tr>
      <tr><td>Adults 18-50</td><td>S. pneumoniae, N. meningitidis</td><td>Ceftriaxone 2g IV q12h + Vancomycin 15-20mg/kg IV q8-12h</td></tr>
      <tr><td>Adults >50 or immunocompromised</td><td>+ Listeria monocytogenes</td><td>Above + Ampicillin 2g IV q4h</td></tr>
      <tr><td>Neurosurgery/head trauma/CSF shunt</td><td>S. aureus, GNR, Pseudomonas</td><td>Vancomycin + Cefepime 2g IV q8h (or Meropenem)</td></tr>
    </table>

    <h4>Dexamethasone</h4>
    <ul>
      <li><strong>Indication:</strong> Give BEFORE or WITH first antibiotic dose if bacterial meningitis suspected</li>
      <li><strong>Dose:</strong> Dexamethasone 0.15 mg/kg IV q6h × 4 days</li>
      <li><strong>Benefit:</strong> Reduces mortality and hearing loss in pneumococcal meningitis; less clear for other organisms</li>
      <li><strong>Discontinue if:</strong> CSF gram stain/culture shows non-pneumococcal organism (some experts continue regardless)</li>
    </ul>

    <h4>CSF Interpretation</h4>
    <table>
      <tr><th>Parameter</th><th>Bacterial</th><th>Viral</th><th>TB/Fungal</th></tr>
      <tr><td>WBC</td><td>>1000 (often >5000)</td><td>10-500</td><td>50-500</td></tr>
      <tr><td>Differential</td><td>>80% PMN</td><td>Lymphocyte predominant</td><td>Lymphocyte predominant</td></tr>
      <tr><td>Glucose</td><td><40 mg/dL (or CSF:serum <0.4)</td><td>Normal</td><td>Low</td></tr>
      <tr><td>Protein</td><td>>200 mg/dL</td><td>50-100</td><td>100-500</td></tr>
      <tr><td>Opening pressure</td><td>Elevated (>20 cmH2O)</td><td>Normal/mild ↑</td><td>Often elevated</td></tr>
    </table>
    <p><strong>Pearl:</strong> Early bacterial meningitis or partially treated may show lymphocyte predominance. Repeat LP in 12-24h if uncertain.</p>
  </div>

  <button class="collapsible">Necrotizing Fasciitis</button>
  <div class="panel">
    <h4>Key Principles</h4>
    <ul>
      <li><strong>SURGICAL EMERGENCY:</strong> Mortality increases 7-9% for every hour of delay in debridement</li>
      <li><strong>Types:</strong> Type I (polymicrobial, diabetics/elderly), Type II (Group A Strep or S. aureus monomicrobial)</li>
      <li><strong>Clinical clues:</strong> Pain out of proportion, rapid progression, crepitus, bullae, skin necrosis, systemic toxicity</li>
    </ul>

    <h4>LRINEC Score (Laboratory Risk Indicator for Necrotizing Fasciitis)</h4>
    <table>
      <tr><th>Variable</th><th>Value</th><th>Points</th></tr>
      <tr><td>CRP</td><td>≥150 mg/L</td><td>4</td></tr>
      <tr><td>WBC</td><td>15-25</td><td>1</td></tr>
      <tr><td>WBC</td><td>>25</td><td>2</td></tr>
      <tr><td>Hemoglobin</td><td>11-13.5 g/dL</td><td>1</td></tr>
      <tr><td>Hemoglobin</td><td><11 g/dL</td><td>2</td></tr>
      <tr><td>Sodium</td><td><135 mEq/L</td><td>2</td></tr>
      <tr><td>Creatinine</td><td>>1.6 mg/dL</td><td>2</td></tr>
      <tr><td>Glucose</td><td>>180 mg/dL</td><td>1</td></tr>
    </table>
    <p><strong>Interpretation:</strong> ≥6 = high suspicion (PPV 92%); ≥8 = strongly predictive. But <strong>do NOT use to rule out</strong>—low score doesn't exclude nec fasc!</p>

    <h4>Empiric Therapy</h4>
    <ul>
      <li><strong>Broad-spectrum:</strong> Vancomycin + Piperacillin-tazobactam (or Meropenem) + Clindamycin</li>
      <li><strong>Clindamycin rationale:</strong> Inhibits toxin production (Eagle effect—severe GAS may not respond to beta-lactams alone in high inoculum)</li>
      <li><strong>Duration:</strong> Continue until debridements complete, clinically stable, cultures guide de-escalation</li>
    </ul>

    <h4>Surgical Principles</h4>
    <ul>
      <li>OR within 12-24 hours of presentation (ideally within 6h)</li>
      <li>Finger test: If tissue planes dissect easily with blunt finger, confirms diagnosis</li>
      <li>Repeat debridement every 24-48h until clean margins</li>
      <li>Consider IVIG for streptococcal toxic shock (2g/kg single dose)</li>
    </ul>
  </div>

  <button class="collapsible">Diabetic Foot Infections</button>
  <div class="panel">
    <h4>IDSA/IWGDF Classification</h4>
    <table>
      <tr><th>Grade</th><th>Clinical Features</th><th>Management</th></tr>
      <tr><td><strong>1 - Uninfected</strong></td><td>Wound without signs of infection</td><td>Wound care, offloading</td></tr>
      <tr><td><strong>2 - Mild</strong></td><td>Local infection, erythema ≤2cm from wound, limited to skin/subQ</td><td>Oral abx, outpatient (1-2 weeks)</td></tr>
      <tr><td><strong>3 - Moderate</strong></td><td>Erythema >2cm, or deeper than skin/subQ (abscess, fascia, muscle, bone, joint)</td><td>IV abx, hospitalize, surgical eval (2-4 weeks)</td></tr>
      <tr><td><strong>4 - Severe</strong></td><td>Local infection + SIRS (fever, HR >90, RR >20, WBC >12k or <4k)</td><td>IV abx, hospitalize, urgent surgery (2-4 weeks)</td></tr>
    </table>

    <h4>Microbiology</h4>
    <ul>
      <li><strong>Acute, mild:</strong> Often gram-positive (S. aureus, Strep)</li>
      <li><strong>Chronic, severe, prior abx:</strong> Polymicrobial—add GNR, Pseudomonas, anaerobes</li>
      <li><strong>Always culture:</strong> Deep tissue or bone, not superficial swab</li>
    </ul>

    <h4>Empiric Antibiotic Selection</h4>
    <table>
      <tr><th>Severity</th><th>No MRSA/Pseudomonas Risk</th><th>MRSA/Pseudomonas Risk</th></tr>
      <tr><td>Mild</td><td>Amoxicillin-clavulanate OR TMP-SMX + Amoxicillin</td><td>TMP-SMX or Doxycycline</td></tr>
      <tr><td>Moderate</td><td>Ampicillin-sulbactam OR Ceftriaxone + Metronidazole</td><td>Vancomycin + Ceftazidime or Pip-Tazo</td></tr>
      <tr><td>Severe</td><td>Piperacillin-tazobactam</td><td>Vancomycin + Piperacillin-tazobactam (or Meropenem)</td></tr>
    </table>

    <h4>Osteomyelitis Considerations</h4>
    <ul>
      <li><strong>Probe-to-bone test:</strong> If sterile probe reaches bone through ulcer → 87% PPV for osteo</li>
      <li><strong>MRI:</strong> Most sensitive/specific imaging; get if probe positive or high clinical suspicion</li>
      <li><strong>Duration:</strong> 4-6 weeks if residual infected bone; may be shorter if complete resection</li>
    </ul>

    <h4>Amputation Considerations</h4>
    <ul>
      <li>Unreconstructable vascular disease with tissue loss</li>
      <li>Uncontrolled sepsis despite debridement</li>
      <li>Non-functional limb even if infection controlled</li>
      <li>Extensive tissue necrosis beyond salvage</li>
      <li>Patient preference (especially if prolonged treatment/disability expected)</li>
    </ul>
  </div>

  <button class="collapsible">Prosthetic Joint Infection (PJI)</button>
  <div class="panel">
    <h4>MSIS Criteria (2018 Definition)</h4>
    <p><strong>Definite PJI:</strong> ≥1 major criterion OR ≥3 minor criteria (≥6 points)</p>
    <p><strong>Major Criteria (diagnostic):</strong></p>
    <ul>
      <li>Two positive periprosthetic cultures with identical organism</li>
      <li>Sinus tract communicating with joint</li>
    </ul>
    <p><strong>Minor Criteria (weighted scoring):</strong></p>
    <table>
      <tr><th>Criterion</th><th>Points</th></tr>
      <tr><td>Elevated serum CRP (>10 mg/L) AND ESR (>30)</td><td>2</td></tr>
      <tr><td>Elevated synovial WBC (>3000) OR ++ leukocyte esterase</td><td>3</td></tr>
      <tr><td>Elevated synovial PMN% (>80%)</td><td>2</td></tr>
      <tr><td>Single positive culture</td><td>2</td></tr>
      <tr><td>Positive histopathology</td><td>3</td></tr>
    </table>

    <h4>Treatment Strategy</h4>
    <table>
      <tr><th>Scenario</th><th>Strategy</th></tr>
      <tr><td>Acute (<4 wks from implant) or acute hematogenous (<3 wks symptoms)</td><td>DAIR (Debridement, Antibiotics, Implant Retention) + 6 weeks IV then oral suppression</td></tr>
      <tr><td>Chronic (>4 wks from implant, >3 wks symptoms)</td><td>Two-stage exchange (spacer with abx cement, 6+ wks abx, then reimplant)</td></tr>
      <tr><td>Highly virulent/difficult organism (MRSA, resistant GNR)</td><td>Two-stage exchange preferred</td></tr>
    </table>

    <h4>Antibiotic Principles</h4>
    <ul>
      <li><strong>Staph:</strong> Add rifampin (biofilm activity) once wound stable; use with companion drug (quinolone, TMP-SMX)</li>
      <li><strong>Duration:</strong> 6 weeks for hip, 12 weeks for knee (if DAIR); may extend for two-stage</li>
      <li><strong>Suppressive therapy:</strong> May be lifelong if implant retained and high risk of relapse</li>
    </ul>
  </div>

  <button class="collapsible">CLABSI (Central Line-Associated Bloodstream Infection)</button>
  <div class="panel">
    <h4>Definition (NHSN/CDC)</h4>
    <ul>
      <li>Central line in place >2 days AND on day of or day before BSI</li>
      <li>Blood culture positive for recognized pathogen OR common commensal from ≥2 separate cultures</li>
      <li>No other apparent source</li>
    </ul>

    <h4>Common Pathogens</h4>
    <ul>
      <li>Coagulase-negative Staphylococci (most common)</li>
      <li>S. aureus (MSSA & MRSA)</li>
      <li>Enterococcus</li>
      <li>Candida species</li>
      <li>Gram-negative rods (Klebsiella, E. coli, Pseudomonas, Enterobacter)</li>
    </ul>

    <h4>Management by Organism</h4>
    <table>
      <tr><th>Organism</th><th>Line Removal</th><th>Duration</th></tr>
      <tr><td>S. aureus</td><td><strong>REMOVE</strong> (always)</td><td>4-6 weeks if complicated; 2 weeks if uncomplicated, TEE negative</td></tr>
      <tr><td>Candida</td><td><strong>REMOVE</strong> (always)</td><td>14 days from first negative culture</td></tr>
      <tr><td>Pseudomonas</td><td><strong>REMOVE</strong></td><td>7-14 days</td></tr>
      <tr><td>Enterococcus</td><td>Remove recommended</td><td>7-14 days</td></tr>
      <tr><td>Coag-neg Staph</td><td>May salvage with abx lock therapy</td><td>5-7 days if line removed; 10-14 days if retained</td></tr>
      <tr><td>GNR (non-Pseudomonas)</td><td>Attempt salvage possible</td><td>7-14 days</td></tr>
    </table>

    <h4>Complicated CLABSI (Requires Longer Therapy)</h4>
    <ul>
      <li>Persistent bacteremia >72h despite appropriate therapy and line removal</li>
      <li>Endocarditis (get TTE, consider TEE especially for S. aureus)</li>
      <li>Septic thrombophlebitis</li>
      <li>Osteomyelitis or metastatic infection</li>
    </ul>
  </div>

  <button class="collapsible">Spinal Epidural Abscess</button>
  <div class="panel">
    <h4>Classic Triad (present in <15%)</h4>
    <ul>
      <li>Fever</li>
      <li>Back pain (most common presenting symptom—95%)</li>
      <li>Neurologic deficit (late finding)</li>
    </ul>

    <h4>Risk Factors</h4>
    <ul>
      <li>IVDU, diabetes, immunosuppression, alcoholism</li>
      <li>Recent spinal procedure or epidural catheter</li>
      <li>Distant infection (bacteremia, skin/soft tissue)</li>
      <li>Degenerative spine disease</li>
    </ul>

    <h4>Diagnosis</h4>
    <ul>
      <li><strong>MRI with gadolinium:</strong> Imaging of choice—entire spine if clinical localization unclear</li>
      <li><strong>Blood cultures:</strong> Positive in 60-70%</li>
      <li><strong>Labs:</strong> Elevated WBC, ESR (usually >30), CRP</li>
    </ul>

    <h4>Microbiology</h4>
    <ul>
      <li>S. aureus: 60-70% (MRSA common)</li>
      <li>Gram-negative rods: 15% (especially with UTI source)</li>
      <li>Streptococci: 10%</li>
      <li>TB: Consider in endemic areas or immunocompromised</li>
    </ul>

    <h4>Management</h4>
    <ul>
      <li><strong>Empiric:</strong> Vancomycin + Ceftriaxone (or Cefepime if Pseudomonas risk)</li>
      <li><strong>Surgery:</strong> Urgent decompression if neurologic deficits or progression, failure of medical therapy, or instability</li>
      <li><strong>Medical management alone:</strong> Consider if no neuro deficits, small abscess, high surgical risk, improving on abx</li>
      <li><strong>Duration:</strong> 6-8 weeks IV (longer if vertebral osteomyelitis)</li>
    </ul>

    <h4>Prognosis</h4>
    <ul>
      <li>Neurologic outcome correlates with severity and duration of deficits pre-op</li>
      <li>Paralysis >24-48 hours rarely recovers—emphasizes urgency</li>
    </ul>
  </div>

  <button class="collapsible">Febrile Neutropenia</button>
  <div class="panel">
    <h4>Definitions</h4>
    <ul>
      <li><strong>Fever:</strong> Single temp ≥38.3°C OR ≥38.0°C sustained for ≥1 hour</li>
      <li><strong>Neutropenia:</strong> ANC <500/µL OR <1000/µL with expected decline to <500 within 48h</li>
      <li><strong>Profound neutropenia:</strong> ANC <100/µL</li>
      <li><strong>Prolonged neutropenia:</strong> Expected >7 days</li>
    </ul>

    <h4>MASCC Risk Index (Multinational Association for Supportive Care in Cancer)</h4>
    <table>
      <tr><th>Characteristic</th><th>Points</th></tr>
      <tr><td>Burden of illness: Mild or no symptoms</td><td>5</td></tr>
      <tr><td>Burden of illness: Moderate symptoms</td><td>3</td></tr>
      <tr><td>No hypotension (SBP ≥90)</td><td>5</td></tr>
      <tr><td>No COPD</td><td>4</td></tr>
      <tr><td>Solid tumor or no prior fungal infection</td><td>4</td></tr>
      <tr><td>Outpatient at fever onset</td><td>3</td></tr>
      <tr><td>No dehydration</td><td>3</td></tr>
      <tr><td>Age <60 years</td><td>2</td></tr>
    </table>
    <p><strong>Score ≥21:</strong> Low risk—may consider outpatient oral therapy (quinolone + amoxicillin-clavulanate)</p>
    <p><strong>Score <21:</strong> High risk—requires inpatient IV therapy</p>

    <h4>Empiric Therapy</h4>
    <table>
      <tr><th>Risk</th><th>Regimen</th></tr>
      <tr><td>Standard (high-risk)</td><td>Cefepime 2g IV q8h OR Piperacillin-tazobactam 4.5g IV q6h OR Meropenem 1g IV q8h</td></tr>
      <tr><td>+ MRSA risk factors</td><td>Add Vancomycin (hemodynamic instability, skin/catheter infection, pneumonia, known MRSA colonization)</td></tr>
      <tr><td>+ Pseudomonas risk</td><td>Use anti-pseudomonal beta-lactam (cefepime, pip-tazo, meropenem)</td></tr>
      <tr><td>Low risk (outpatient)</td><td>Ciprofloxacin 750mg PO q12h + Amoxicillin-clavulanate 875mg PO q12h</td></tr>
    </table>

    <h4>Add Antifungal If:</h4>
    <ul>
      <li>Persistent fever >4-7 days despite broad-spectrum antibiotics</li>
      <li>Prolonged neutropenia (>10 days expected)</li>
      <li>Hematologic malignancy or HSCT recipient</li>
      <li><strong>Options:</strong> Caspofungin, Micafungin, Liposomal Amphotericin B, Voriconazole (if Aspergillus suspected)</li>
    </ul>

    <h4>Duration</h4>
    <ul>
      <li>Continue until ANC ≥500 AND afebrile for 48h (if source unidentified)</li>
      <li>If documented infection, complete appropriate course for that infection</li>
    </ul>
  </div>
</section>

<!-- SEPSIS -->
<section id="sepsis">
  <h2>Sepsis</h2>

  <button class="collapsible">Immediate Actions (Sepsis Bundle)</button>
  <div class="panel">
    <ul>
      <li>Obtain cultures (blood ×2, site-specific) before antibiotics if feasible — do not delay critical therapy.</li>
      <li>Administer broad-spectrum IV antibiotics within 1 hour.</li>
      <li>Give 30 mL/kg crystalloid bolus for hypotension or lactate ≥4 mmol/L.</li>
      <li>Start vasopressors (norepinephrine preferred) to maintain MAP ≥65 mmHg if hypotension persists.</li>
      <li>Reassess daily; de-escalate when appropriate.</li>
    </ul>
  </div>

  <button class="collapsible">Complications & Monitoring</button>
  <div class="panel">
    <ul>
      <li>Monitor lactate, urine output, mental status, organ function.</li>
      <li>Adjust dosing in renal/hepatic failure and ECMO/CRRT settings.</li>
    </ul>
  </div>
</section>

<!-- PATHOGEN GUIDANCE -->
<section id="pathogen-guidance">
  <h2>Pathogen-Based Guidance (Quick)</h2>

  <button class="collapsible">Gram-Positive Cocci</button>
  <div class="panel">
    <ul>
      <li>MSSA: Anti-staphylococcal penicillins (nafcillin/oxacillin) or cefazolin.</li>
      <li>MRSA: Vancomycin (AUC-based), alternatives: daptomycin (not for pneumonia), linezolid (pneumonia option).</li>
      <li>Enterococcus: Ampicillin if susceptible; VRE → linezolid or daptomycin (dose per weight).</li>
    </ul>
  </div>

  <button class="collapsible">Gram-Negative Rods</button>
  <div class="panel">
    <ul>
      <li>Enterobacteriaceae: ceftriaxone/cefepime/pip-tazo; escalate to carbapenem for ESBL.</li>
      <li>Pseudomonas: cefepime/meropenem/pip-tazo; consider aminoglycoside synergy in severe cases.</li>
      <li>Burkholderia: often multidrug-resistant; use ceftazidime/meropenem/TMP-SMX guided by susceptibilities.</li>
    </ul>
  </div>

  <button class="collapsible">Anaerobes</button>
  <div class="panel">
    <ul>
      <li>Bacteroides: metronidazole with beta-lactam partner, or beta-lactam/beta-lactamase inhibitor; carbapenems for severe disease.</li>
      <li>Actinomyces: prolonged high-dose penicillin therapy (months).</li>
    </ul>
  </div>

  <button class="collapsible">Intracellular/Fastidious</button>
  <div class="panel">
    <ul>
      <li>Legionella: fluoroquinolone or macrolide.</li>
      <li>Chlamydia: doxycycline or macrolide.</li>
      <li>Nocardia: TMP-SMX (often high-dose), alternatives include linezolid, imipenem guided by susceptibility.</li>
    </ul>
  </div>
</section>

<!-- PATHOGEN OVERVIEW -->
<section id="pathogen-overview">
  <h2>Pathogen Overview — Selected Genera (expanded)</h2>

  <button class="collapsible">Escherichia coli</button>
  <div class="panel">
    <ul>
      <li>Gram-negative rod; common cause of UTI, intra-abdominal infection, bacteremia.</li>
      <li>ESBL prevalence variable — check local antibiogram; resistant isolates often require carbapenem.</li>
      <li>Virulence: adhesins, endotoxin; therapy guided by susceptibility.</li>
    </ul>
  </div>

  <button class="collapsible">Klebsiella spp.</button>
  <div class="panel">
    <ul>
      <li>Encapsulated gram-negative rod; causes pneumonia, UTI, liver abscess.</li>
      <li>Carbapenemase producers (KPC, NDM) are significant — infection control & ID consultation recommended.</li>
    </ul>
  </div>

  <button class="collapsible">Pseudomonas aeruginosa</button>
  <div class="panel">
    <ul>
      <li>Non-fermenter; common in HAP/VAP, wound infections, device-related infections.</li>
      <li>Resistance via efflux pumps, porin loss, beta-lactamases; biofilms complicate device infections.</li>
      <li>Therapy: higher dosing, extended infusions of beta-lactams often beneficial; tailor to MICs.</li>
    </ul>
  </div>

  <button class="collapsible">Burkholderia cepacia complex</button>
  <div class="panel">
    <ul>
      <li>Important in cystic fibrosis and immunocompromised hosts; often intrinsically resistant.</li>
      <li>Combination therapy frequently required; consult susceptibility/ID.</li>
    </ul>
  </div>

  <button class="collapsible">Bacteroides fragilis</button>
  <div class="panel">
    <ul>
      <li>Anaerobic gram-negative rod common in intra-abdominal infections; beta-lactamase production common.</li>
      <li>Prefer agents with anaerobic coverage: metronidazole, beta-lactam/beta-lactamase inhibitors, carbapenems.</li>
    </ul>
  </div>

  <button class="collapsible">Actinomyces</button>
  <div class="panel">
    <ul>
      <li>Filamentous, gram-positive anaerobe associated with dental disease and cervicofacial infections.</li>
      <li>Treatment: prolonged high-dose penicillin (months), surgical drainage when required.</li>
    </ul>
  </div>

  <button class="collapsible">Mycobacterium tuberculosis (brief)</button>
  <div class="panel">
    <ul>
      <li>Acid-fast bacillus; RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) initial phase.</li>
      <li>Diagnosis and management require public health and specialist involvement due to public health implications and prolonged therapy.</li>
    </ul>
  </div>

  <button class="collapsible">Nocardia</button>
  <div class="panel">
    <ul>
      <li>Branching, weakly acid-fast filamentous bacterium; pulmonary, disseminated and CNS disease seen in immunocompromised.</li>
      <li>Treatment: TMP-SMX backbone; duration 6–12 months depending on site; consider linezolid/imipenem depending on species.</li>
    </ul>
  </div>

  <button class="collapsible">Clostridioides difficile</button>
  <div class="panel">
    <ul>
      <li>Spore-forming anaerobe causing antibiotic-associated colitis; severe disease may cause toxic megacolon.</li>
      <li>Treatment: oral vancomycin or fidaxomicin for initial episode; fecal microbiota transplant for recurrent disease per guidelines.</li>
    </ul>
  </div>

  <!-- Additional High-Yield Pathogens -->
  <button class="collapsible">VRE (Vancomycin-Resistant Enterococcus)</button>
  <div class="panel">
    <ul>
      <li><strong>Species:</strong> Primarily E. faecium (vanA, vanB genes); E. faecalis less common</li>
      <li><strong>Risk factors:</strong> Prior vancomycin, prolonged hospitalization, ICU, immunosuppression, GI colonization</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li>Linezolid 600mg IV/PO q12h (preferred for many infections, oral bioavailability 100%)</li>
          <li>Daptomycin 6-8 mg/kg IV daily (higher doses for bacteremia 8-12 mg/kg; NOT for pneumonia)</li>
          <li>Tigecycline (for intra-abdominal/skin only; poor serum levels)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> UTI 5-7 days; bacteremia 7-14 days; endocarditis 6 weeks (ID consult)</li>
      <li><strong>Pearl:</strong> VRE bacteremia—remove lines if present; search for intra-abdominal/biliary source</li>
    </ul>
  </div>

  <button class="collapsible">ESBL Producers (Extended-Spectrum Beta-Lactamase)</button>
  <div class="panel">
    <ul>
      <li><strong>Organisms:</strong> E. coli, Klebsiella pneumoniae, Proteus mirabilis most common</li>
      <li><strong>Resistance pattern:</strong> Resistant to 3rd-gen cephalosporins (ceftriaxone, ceftazidime), aztreonam; often co-resistant to fluoroquinolones, TMP-SMX</li>
      <li><strong>Risk factors:</strong> Prior 3rd-gen cephalosporin or fluoroquinolone use, healthcare exposure, travel to endemic areas (India, Middle East)</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Severe infections/bacteremia:</strong> Meropenem 1g IV q8h or Ertapenem 1g IV daily (carbapenems are treatment of choice)</li>
          <li><strong>UTI (uncomplicated):</strong> May use nitrofurantoin, fosfomycin if susceptible; TMP-SMX if susceptible</li>
          <li><strong>Pip-tazo:</strong> May be used if MIC ≤16 and non-critically ill (controversial—MERINO trial suggests carbapenem superiority for bacteremia)</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Always confirm susceptibilities; report may show cephalosporin "susceptible" but clinical failure can occur</li>
    </ul>
  </div>

  <button class="collapsible">CRE (Carbapenem-Resistant Enterobacteriaceae)</button>
  <div class="panel">
    <ul>
      <li><strong>Organisms:</strong> K. pneumoniae (KPC most common in US), E. coli, Enterobacter</li>
      <li><strong>Mechanisms:</strong> KPC (Klebsiella pneumoniae carbapenemase), NDM, OXA-48, VIM, IMP</li>
      <li><strong>Risk factors:</strong> Prior carbapenems, prolonged hospitalization, ICU, mechanical ventilation, international travel (NDM—South Asia)</li>
      <li><strong>Treatment (ID consult strongly recommended):</strong>
        <ul>
          <li><strong>Ceftazidime-avibactam:</strong> 2.5g IV q8h—covers KPC and OXA-48 (NOT NDM)</li>
          <li><strong>Meropenem-vaborbactam:</strong> 4g IV q8h—covers KPC</li>
          <li><strong>Imipenem-relebactam:</strong> Alternative for KPC</li>
          <li><strong>Cefiderocol:</strong> Siderophore cephalosporin—covers NDM, difficult GNRs</li>
          <li><strong>Combination therapy:</strong> Consider for severe infections (e.g., high-dose meropenem + polymyxin or aminoglycoside)</li>
        </ul>
      </li>
      <li><strong>Mortality:</strong> 40-50% for CRE bacteremia—highlights severity</li>
      <li><strong>Infection control:</strong> Contact precautions, aggressive screening, single rooms</li>
    </ul>
  </div>

  <button class="collapsible">Acinetobacter baumannii</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-negative coccobacillus, environmental persistence, rapid resistance development</li>
      <li><strong>Clinical syndromes:</strong> VAP (most common), CLABSI, wound infections, meningitis (post-neurosurgical)</li>
      <li><strong>Risk factors:</strong> ICU, mechanical ventilation, prior broad-spectrum antibiotics, wounds/burns, deployed military</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>MDR Acinetobacter:</strong> Ampicillin-sulbactam (high dose 9g IV q8h—sulbactam has intrinsic activity)</li>
          <li><strong>XDR/pan-resistant:</strong> Polymyxin B or Colistin (often in combination)</li>
          <li><strong>Sulbactam-durlobactam (Xacduro):</strong> Newly approved for hospital-acquired pneumonia</li>
          <li><strong>Tigecycline:</strong> May be used for non-bacteremic infections (achieves poor serum levels)</li>
          <li><strong>Combination therapy:</strong> Often used for severe infections (carbapenem + polymyxin if any susceptibility)</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Colonization vs. infection distinction important—may not need treatment if just colonizing respiratory tract</li>
    </ul>
  </div>

  <button class="collapsible">Stenotrophomonas maltophilia</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Intrinsically resistant to carbapenems (L1 and L2 beta-lactamases)</li>
      <li><strong>Clinical syndromes:</strong> Pneumonia (especially VAP), CLABSI, wound infections, often in immunocompromised/CF patients</li>
      <li><strong>Risk factors:</strong> Prior carbapenems, prolonged hospitalization, ICU, malignancy, steroids, CF</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h</li>
          <li><strong>Alternatives:</strong> Levofloxacin, Minocycline, Ticarcillin-clavulanate, Ceftazidime-avibactam (check susceptibility)</li>
          <li><strong>Severe infections:</strong> Consider combination therapy (TMP-SMX + fluoroquinolone or minocycline)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 7-14 days depending on source</li>
      <li><strong>Pearl:</strong> Do NOT use carbapenems—intrinsic resistance; monotherapy may select further resistance</li>
    </ul>
  </div>

  <button class="collapsible">Listeria monocytogenes</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-positive rod, facultative intracellular, grows at refrigerator temps</li>
      <li><strong>Clinical syndromes:</strong> Meningitis, bacteremia, rhombencephalitis (brainstem), gastroenteritis, maternal-fetal infection</li>
      <li><strong>Risk factors:</strong> Age >50, pregnancy, immunocompromise (steroids, transplant, HIV), cirrhosis, diabetes, iron overload</li>
      <li><strong>Source:</strong> Contaminated food—deli meats, soft cheeses, unpasteurized dairy, cantaloupe</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> Ampicillin 2g IV q4h (± Gentamicin for synergy in severe/meningitis)</li>
          <li><strong>Penicillin allergy:</strong> TMP-SMX (Bactrim) 10-20 mg/kg/day TMP component</li>
          <li><strong>NOT susceptible to:</strong> Cephalosporins (important—why ampicillin added to meningitis empiric regimen in elderly)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> Bacteremia 2 weeks; meningitis 3+ weeks; rhombencephalitis/brain abscess 6+ weeks</li>
      <li><strong>Pearl:</strong> CSF may show mononuclear predominance and only mildly elevated protein—can mimic viral/TB</li>
    </ul>
  </div>

  <button class="collapsible">Legionella pneumophila</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-negative rod (stains poorly), obligate intracellular, environmental (water systems)</li>
      <li><strong>Clinical syndromes:</strong> Atypical pneumonia, Pontiac fever (self-limited febrile illness)</li>
      <li><strong>Risk factors:</strong> Smoking, COPD, immunosuppression, age >50, recent travel, hospital water exposure</li>
      <li><strong>Clinical clues:</strong> High fever, relative bradycardia, hyponatremia, diarrhea, confusion, elevated LFTs, low phosphorus</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Urine antigen:</strong> Serogroup 1 only (most common), 80% sensitive, 99% specific, remains positive for weeks</li>
          <li><strong>Respiratory culture:</strong> Requires special media (BCYE agar)—specify Legionella if suspected</li>
          <li><strong>PCR:</strong> Increasingly available</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Preferred:</strong> Levofloxacin 750mg IV/PO daily OR Azithromycin 500mg IV/PO daily</li>
          <li><strong>Severe/immunocompromised:</strong> Consider combination (fluoroquinolone + azithromycin) initially</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 5-10 days (mild); 14-21 days (severe/immunocompromised)</li>
    </ul>
  </div>

  <button class="collapsible">PJP (Pneumocystis jirovecii Pneumonia)</button>
  <div class="panel">
    <ul>
      <li><strong>Epidemiology:</strong> Fungal infection in immunocompromised—HIV (CD4 <200), transplant, high-dose steroids, hematologic malignancy</li>
      <li><strong>Clinical:</strong> Subacute dyspnea (days to weeks), dry cough, fever, hypoxemia with exertion; desaturation with ambulation</li>
      <li><strong>Imaging:</strong> Bilateral interstitial/ground-glass infiltrates, often perihilar; can be normal early or atypical (nodules, cysts, pneumothorax)</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Induced sputum:</strong> 50-90% sensitive if available</li>
          <li><strong>BAL:</strong> >95% sensitive—gold standard</li>
          <li><strong>Beta-D-glucan:</strong> Elevated (>80 pg/mL), good negative predictive value</li>
          <li><strong>LDH:</strong> Typically elevated (non-specific)</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h × 21 days</li>
          <li><strong>Adjunctive steroids (if PaO2 <70 or A-a gradient >35):</strong> Prednisone 40mg PO BID × 5 days, then 40mg daily × 5, then 20mg daily × 11</li>
          <li><strong>Alternatives:</strong> Pentamidine IV, Atovaquone (mild), Clindamycin + Primaquine (moderate)</li>
        </ul>
      </li>
      <li><strong>Prophylaxis indications:</strong> HIV with CD4 <200, HSCT, high-dose steroids (≥20mg prednisone × 4+ weeks), certain chemo/biologics</li>
    </ul>
  </div>

  <button class="collapsible">CMV in Immunocompromised</button>
  <div class="panel">
    <ul>
      <li><strong>Populations:</strong> Transplant (SOT, HSCT), HIV (CD4 <50), high-dose steroids/biologics</li>
      <li><strong>Clinical syndromes:</strong> Colitis (diarrhea, bleeding), Pneumonitis, Retinitis, Hepatitis, Encephalitis</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>CMV PCR (blood):</strong> Quantitative viral load—for monitoring, rising VL suggests active disease</li>
          <li><strong>Tissue biopsy:</strong> Owl's eye inclusions, immunohistochemistry—gold standard for end-organ disease</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Ganciclovir:</strong> 5 mg/kg IV q12h (induction 2-3 weeks), then 5 mg/kg IV daily (maintenance)</li>
          <li><strong>Valganciclovir:</strong> 900mg PO BID (induction), then 900mg PO daily—oral option if absorbing</li>
          <li><strong>Foscarnet:</strong> For ganciclovir-resistant CMV or if neutropenic; nephrotoxic, electrolyte wasting</li>
        </ul>
      </li>
      <li><strong>Monitoring:</strong> Weekly CMV PCR during treatment; toxicities (neutropenia, thrombocytopenia, renal for foscarnet)</li>
    </ul>
  </div>

  <button class="collapsible">HSV/VZV in Immunocompromised</button>
  <div class="panel">
    <ul>
      <li><strong>HSV Reactivation:</strong>
        <ul>
          <li>Mucocutaneous (oral, genital)—can be severe, hemorrhagic, disseminated</li>
          <li>Esophagitis: Odynophagia, discrete ulcers on EGD</li>
          <li>Hepatitis: Rare, severe, high mortality</li>
          <li>Encephalitis: Even in immunocompetent—temporal lobe</li>
        </ul>
      </li>
      <li><strong>HSV Treatment:</strong>
        <ul>
          <li><strong>Mucocutaneous:</strong> Acyclovir 400mg PO TID or Valacyclovir 1g BID × 7-14 days; IV if severe</li>
          <li><strong>Disseminated/Visceral:</strong> Acyclovir 10 mg/kg IV q8h × 14-21 days</li>
          <li><strong>Encephalitis:</strong> Acyclovir 10 mg/kg IV q8h × 14-21 days</li>
        </ul>
      </li>
      <li><strong>VZV Reactivation (Shingles):</strong>
        <ul>
          <li>Dermatomal vesicles on erythematous base; can disseminate in immunocompromised</li>
          <li>Complications: PHN, HZO (ophthalmic), Ramsay Hunt, meningoencephalitis, VZV vasculopathy</li>
        </ul>
      </li>
      <li><strong>VZV Treatment:</strong>
        <ul>
          <li><strong>Localized (immunocompetent):</strong> Valacyclovir 1g PO TID × 7 days</li>
          <li><strong>Immunocompromised or disseminated:</strong> Acyclovir 10 mg/kg IV q8h until no new lesions × 48h, then oral to complete 10-14 days</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Adjust acyclovir for renal function; ensure adequate hydration (crystalluria risk)</li>
    </ul>
  </div>

  <button class="collapsible">MAC (Mycobacterium avium Complex)</button>
  <div class="panel">
    <ul>
      <li><strong>Epidemiology:</strong> Environmental NTM (water, soil); disease in HIV (CD4 <50), structural lung disease, bronchiectasis, CF</li>
      <li><strong>Clinical Syndromes:</strong>
        <ul>
          <li><strong>Disseminated (HIV):</strong> Fever, night sweats, weight loss, diarrhea, hepatosplenomegaly, cytopenias</li>
          <li><strong>Pulmonary (non-HIV):</strong> Chronic cough, nodular infiltrates, bronchiectasis (Lady Windermere syndrome—RML/lingula)</li>
        </ul>
      </li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Disseminated:</strong> Blood culture (isolator/lysis centrifugation), bone marrow biopsy</li>
          <li><strong>Pulmonary:</strong> ATS/IDSA criteria—symptoms + imaging + microbiology (2+ sputum cultures OR 1 BAL OR tissue)</li>
        </ul>
      </li>
      <li><strong>Treatment (always multidrug):</strong>
        <ul>
          <li><strong>Core regimen:</strong> Azithromycin 250-500mg daily (or Clarithromycin) + Ethambutol 15 mg/kg daily + Rifampin (or Rifabutin for HIV)</li>
          <li><strong>Severe/disseminated:</strong> Add Amikacin or Streptomycin initially</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 12 months after culture-negative (pulmonary); lifelong suppression may be needed in HIV</li>
      <li><strong>Prophylaxis (HIV with CD4 <50):</strong> Azithromycin 1200mg weekly (less common now with effective ART)</li>
    </ul>
  </div>
</section>

<!-- ANTIBIOTIC CLASSES -->
<section id="antibiotic-classes">
  <h2>Antibiotic Classes & Escalation</h2>
  <table>
    <thead><tr><th>Class</th><th>Examples</th><th>Typical Use</th><th>Key Notes</th></tr></thead>
    <tbody>
      <tr><td>Penicillins</td><td>Amoxicillin, Ampicillin, Piperacillin-tazobactam</td><td>Strep, Enterococcus (amp), GN/anaerobes (pip-tazo)</td><td>Check allergy; renal adjust</td></tr>
      <tr><td>Cephalosporins</td><td>Cefazolin, Ceftriaxone, Cefepime</td><td>Varies by generation; cefepime for Pseudomonas</td><td>ESBL producers resistant</td></tr>
      <tr><td>Carbapenems</td><td>Meropenem, Imipenem</td><td>Broad GN including ESBL; severe polymicrobial</td><td>Reserve when possible</td></tr>
      <tr><td>Glycopeptides</td><td>Vancomycin</td><td>MRSA, serious GP infections</td><td>Monitor AUC/renal</td></tr>
      <tr><td>Oxazolidinones</td><td>Linezolid</td><td>VRE, MRSA alternatives</td><td>Thrombocytopenia risk, serotonin interactions</td></tr>
    </tbody>
  </table>
</section>

<!-- FUNGAL -->
<section id="fungal-infections">
  <h2>Fungal Infections</h2>

  <button class="collapsible">Candida (candidemia)</button>
  <div class="panel">
    <ul>
      <li>Empiric: Echinocandin (micafungin/caspofungin) IV for critically ill.</li>
      <li>Step-down: Fluconazole for susceptible species after clearance and ID consultation.</li>
      <li>Duration: 14 days after first negative blood culture if uncomplicated.</li>
    </ul>
  </div>

  <button class="collapsible">Aspergillus</button>
  <div class="panel">
    <ul>
      <li>Voriconazole first-line for invasive aspergillosis (weight-based IV dosing then PO); consider TDM.</li>
      <li>Liposomal amphotericin B for intolerance or certain species.</li>
    </ul>
  </div>

  <button class="collapsible">Cryptococcus</button>
  <div class="panel">
    <ul>
      <li>Induction: liposomal amphotericin B + flucytosine; consolidation/maintenance with fluconazole per guidelines.</li>
      <li>Consult ID for CNS disease and immunocompromised hosts.</li>
    </ul>
  </div>

  <button class="collapsible">Mucorales</button>
  <div class="panel">
    <ul>
      <li>Liposomal amphotericin B 5–10 mg/kg IV daily; urgent surgical debridement and control of underlying risk factors (e.g., hyperglycemia).</li>
    </ul>
  </div>
</section>

<!-- VIRAL -->
<section id="viral-infections">
  <h2>Viral Infections</h2>
  <table>
    <thead><tr><th>Virus</th><th>Therapy</th><th>Dose / Notes</th></tr></thead>
    <tbody>
      <tr><td>Influenza A/B</td><td>Oseltamivir</td><td>75 mg PO BID ×5 d (longer if severe)</td></tr>
      <tr><td>HSV-1 / HSV-2 (severe/encephalitis)</td><td>Acyclovir</td><td>10 mg/kg IV q8h ×14–21 d for encephalitis (adjust renal)</td></tr>
      <tr><td>CMV (organ-invasive)</td><td>Ganciclovir / Valganciclovir</td><td>Ganciclovir 5 mg/kg IV q12h induction; monitor counts</td></tr>
      <tr><td>RSV (severe)</td><td>Supportive / Ribavirin in select</td><td>Consider in transplant/infants per local protocols</td></tr>
    </tbody>
  </table>
  
  <button class="collapsible">Viral Hepatitis — HAV, HBV, HCV, HDV, HEV</button>
  <div class="panel">
    <ul>
      <li><strong>Hepatitis A (HAV):</strong> Supportive care only; self-limited. Post-exposure prophylaxis for close contacts: HAV vaccine (age 1-40) or immunoglobulin.</li>
      <li><strong>Hepatitis B (Acute):</strong> Supportive care; 95% of adults clear spontaneously. Antivirals (tenofovir, entecavir) only if severe/protracted course, acute liver failure, or immunocompromised.</li>
      <li><strong>Hepatitis B (Chronic):</strong> Tenofovir disoproxil (TDF) 300 mg daily or Entecavir 0.5 mg daily (1 mg if lamivudine-resistant). Treat if HBV DNA elevated with ALT >2× ULN or fibrosis.</li>
      <li><strong>Hepatitis C:</strong> Direct-acting antivirals (DAAs) - specific regimen based on genotype and fibrosis. Common: Sofosbuvir/velpatasvir (Epclusa) 1 tab daily ×12 weeks. Cure rate >95%.</li>
      <li><strong>Hepatitis D:</strong> Coinfection with HBV only; pegylated interferon-alpha is traditional therapy. Bulevirtide (Hepcludex) newly approved.</li>
      <li><strong>Hepatitis E:</strong> Usually self-limited; chronic in immunocompromised - reduce immunosuppression, consider ribavirin.</li>
      <li><strong>IMCRG Reference:</strong> <a href="im_guide.html#viral-hepatitis" style="color:#004080">#121 Acute Viral Hepatitis</a> - serologic workup, acute liver failure criteria</li>
    </ul>
  </div>
</section>

<!-- TICKBORNE -->
<section id="tickborne-infections">
  <h2>Tickborne Infections</h2>

  <button class="collapsible">Lyme disease — Borrelia burgdorferi</button>
  <div class="panel">
    <ul>
      <li>Early localized (erythema migrans): Doxycycline 100 mg PO BID ×10–21 d.</li>
      <li>Pregnancy/children <8: Amoxicillin 500 mg PO TID ×14–21 d (weight/age adjust) or cefuroxime.</li>
      <li>Neurocardiac Lyme: Ceftriaxone 2 g IV q24h ×14–28 d for neurologic or severe cardiac involvement.</li>
    </ul>
  </div>

  <button class="collapsible">Anaplasmosis / Ehrlichiosis</button>
  <div class="panel">
    <ul>
      <li>Empiric: Doxycycline 100 mg PO/IV twice daily ×10–14 d; treat promptly on suspicion regardless of age.</li>
      <li>Presentation: fever, cytopenias, elevated LFTs; can be severe in immunocompromised.</li>
    </ul>
  </div>

  <button class="collapsible">Babesiosis</button>
  <div class="panel">
    <ul>
      <li>Mild–moderate: Atovaquone 750 mg PO BID + Azithromycin 500 mg PO day1 then 250 mg PO daily ×7–10 d.</li>
      <li>Severe: Clindamycin + Quinine IV; consider exchange transfusion for high parasitemia or severe hemolysis.</li>
    </ul>
  </div>

  <button class="collapsible">Rocky Mountain Spotted Fever</button>
  <div class="panel">
    <ul>
      <li>Empiric: Doxycycline 100 mg PO/IV BID for adults and children; treat immediately on suspicion.</li>
      <li>Duration typically 5–14 d depending on clinical course.</li>
    </ul>
  </div>
</section>

<!-- VIRAL ENCEPHALOPATHIES -->
<section id="viral-encephalopathies">
  <h2>Viral Encephalopathies / Arboviral Encephalitis</h2>

  <button class="collapsible">West Nile Virus (WNV)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus transmitted by Culex mosquitoes; most infections asymptomatic or mild febrile illness.</li>
      <li>Neuroinvasive disease: meningitis, encephalitis, acute flaccid paralysis — supportive care only (ICU as needed).</li>
      <li>Diagnosis: CSF/serum IgM, PCR early; consider neuroimaging and EEG for encephalopathy.</li>
    </ul>
  </div>

  <button class="collapsible">Eastern Equine Encephalitis (EEE)</button>
  <div class="panel">
    <ul>
      <li>Alphavirus with high mortality; supportive ICU care, aggressive management of seizures and intracranial pressure.</li>
      <li>No proven antiviral therapy; early recognition and supportive measures crucial.</li>
    </ul>
  </div>

  <button class="collapsible">St. Louis Encephalitis (SLE)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus transmitted by mosquitoes; elderly at higher risk for severe neuroinvasive disease.</li>
      <li>Treatment supportive; involve neurology/ICU for severe cases.</li>
    </ul>
  </div>

  <button class="collapsible">Japanese Encephalitis (JEV)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus endemic in Asia; severe encephalitis possible in a subset.</li>
      <li>Prevention: vaccine for travelers/residents in endemic areas; treatment supportive.</li>
    </ul>
  </div>

  <button class="collapsible">Rabies (neurologic phase)</button>
  <div class="panel">
    <ul>
      <li>Once symptomatic, rabies is almost universally fatal; immediate post-exposure prophylaxis (vaccine + RIG) is critical after exposures.</li>
      <li>If symptomatic, supportive ICU care; consult public health and infectious disease immediately.</li>
    </ul>
  </div>

  <button class="collapsible">HSV Encephalitis</button>
  <div class="panel">
    <ul>
      <li>HSV-1 is the most common cause of sporadic viral encephalitis in adults.</li>
      <li>Treatment: Acyclovir 10 mg/kg IV q8h (adjust renal) for 14–21 days; start immediately if suspected.</li>
    </ul>
  </div>
</section>

<!-- CALCULATORS -->
<section id="calculators">
  <h2>Calculators</h2>

  <div class="calculator" aria-labelledby="crcl-heading">
    <h3 id="crcl-heading">CrCl (Cockcroft-Gault)</h3>
    <div style="display:flex;gap:10px;flex-wrap:wrap;align-items:center">
      <label>Weight (kg): <input id="wt" type="number" style="width:110px"></label>
      <label>Age (yr): <input id="age" type="number" style="width:90px"></label>
      <label>Serum Cr (mg/dL): <input id="cr" type="number" step="0.01" style="width:110px"></label>
      <label>Female? <input id="female" type="checkbox" /></label>
      <button onclick="calcCrCl()" style="padding:6px 10px">Calculate</button>
    </div>
    <p id="crclResult" class="muted" style="margin-top:8px"></p>
  </div>

  <div class="calculator" aria-labelledby="sirs-heading">
    <h3 id="sirs-heading">SIRS / qSOFA Quick</h3>
    <div style="display:flex;gap:10px;flex-wrap:wrap;align-items:center">
      <label>Temp (°C): <input id="temp" type="number" step="0.1" style="width:90px"></label>
      <label>HR: <input id="hr" type="number" style="width:80px"></label>
      <label>RR: <input id="rr" type="number" style="width:80px"></label>
      <label>MAP: <input id="map" type="number" style="width:90px"></label>
      <label>Mental: 
        <select id="mental">
          <option value="alert">alert</option>
          <option value="confused">confused</option>
          <option value="unresponsive">unresponsive</option>
        </select>
      </label>
      <button onclick="calcSIRS_qSOFA()" style="padding:6px 10px">Calculate</button>
    </div>
    <p id="sirsResult" class="muted" style="margin-top:8px"></p>
  </div>
</section>

<!-- REFERENCES -->
<section id="references">
  <h2>References</h2>
  <ul>
    <li><a href="https://www.idsociety.org/practice-guideline/" target="_blank" rel="noopener noreferrer">IDSA Practice Guidelines</a></li>
    <li><a href="https://www.cdc.gov/antibiotic-use/index.html" target="_blank" rel="noopener noreferrer">CDC — Antibiotic Use & Stewardship</a></li>
    <li><a href="https://www.who.int/" target="_blank" rel="noopener noreferrer">WHO</a></li>
    <li>Harrison's Principles of Internal Medicine</li>
    <li>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</li>
  </ul>
</section>

</main>

<script>
/* Sidebar link click - let browser handle anchor navigation natively */
document.querySelectorAll('nav a[href^="#"]').forEach(a=>{
  a.addEventListener('click', e=>{
    // Don't preventDefault - let browser do native anchor navigation
    // scroll-behavior: smooth in CSS handles smooth scrolling
  });
});

/* Collapsible panels: initialization */
function initCollapsibles(){
  document.querySelectorAll('.collapsible').forEach(btn=>{
    // remove previous listener if any to avoid duplicates
    if(btn._listener) btn.removeEventListener('click', btn._listener);
    const listener = function(){
      btn.classList.toggle('active');
      const panel = btn.nextElementSibling;
      if(!panel) return;
      if(panel.style.display === 'block'){
        panel.style.display = 'none';
      } else {
        panel.style.display = 'block';
      }
    };
    btn.addEventListener('click', listener);
    btn._listener = listener;
  });
}
document.addEventListener('DOMContentLoaded', initCollapsibles);

/* Global search/filter that shows matching sections and panels */
function filterAll(query){
  const q = (query||'').trim().toLowerCase();
  // Sections
  document.querySelectorAll('main section').forEach(sec=>{
    const text = sec.innerText.toLowerCase();
    if(!q || text.includes(q)) {
      sec.style.display = '';
    } else {
      sec.style.display = 'none';
    }
  });
  // Buttons & panels
  document.querySelectorAll('.collapsible').forEach(btn=>{
    const panel = btn.nextElementSibling;
    const combined = (btn.innerText + ' ' + (panel?panel.innerText:'' )).toLowerCase();
    if(!q || combined.includes(q)){
      btn.style.display = '';
      if(q && panel && panel.innerText.toLowerCase().includes(q)){
        panel.style.display = 'block';
        btn.classList.add('active');
      }
    } else {
      btn.style.display = 'none';
      if(panel){ panel.style.display = 'none'; btn.classList.remove('active'); }
    }
  });
}

/* Hook global and sidebar search inputs */
const globalSearch = document.getElementById('globalSearch');
const sidebarSearch = document.getElementById('sidebarSearch');
if(globalSearch){
  globalSearch.addEventListener('input', e=>{
    const q = e.target.value;
    if(sidebarSearch) sidebarSearch.value = q;
    filterAll(q);
  });
}
if(sidebarSearch){
  sidebarSearch.addEventListener('input', e=>{
    const q = e.target.value;
    if(globalSearch) globalSearch.value = q;
    filterAll(q);
  });
}

/* Backwards compatibility small helper */
function filterContent(){
  const input = document.getElementById('searchInput');
  if(input) filterAll(input.value);
}

/* Cockcroft-Gault CrCl */
function calcCrCl(){
  const wt = parseFloat(document.getElementById('wt').value);
  const age = parseFloat(document.getElementById('age').value);
  const cr = parseFloat(document.getElementById('cr').value);
  const female = document.getElementById('female').checked;
  const out = document.getElementById('crclResult');
  if(!wt || !age || !cr) { out.innerText = 'Enter weight, age, and serum creatinine.'; return; }
  let crcl = ((140 - age) * wt) / (72 * cr);
  if(female) crcl *= 0.85;
  out.innerText = `Estimated CrCl (Cockcroft-Gault): ${crcl.toFixed(1)} mL/min`;
}

/* SIRS / qSOFA quick */
function calcSIRS_qSOFA(){
  const temp = parseFloat(document.getElementById('temp').value);
  const hr = parseFloat(document.getElementById('hr').value);
  const rr = parseFloat(document.getElementById('rr').value);
  const map = parseFloat(document.getElementById('map').value);
  const mental = document.getElementById('mental').value;
  let sirs = 0;
  if(!isNaN(temp) && (temp < 36 || temp > 38)) sirs++;
  if(!isNaN(hr) && hr > 90) sirs++;
  if(!isNaN(rr) && rr > 20) sirs++;
  let qsofa = 0;
  if(!isNaN(rr) && rr >= 22) qsofa++;
  if(!isNaN(map) && map <= 65) qsofa++;
  if(mental !== 'alert') qsofa++;
  const out = document.getElementById('sirsResult');
  out.innerHTML = `SIRS (partial) criteria met: ${sirs} ${sirs>=2?'<strong>(≥2 suggests SIRS)</strong>':''}<br>qSOFA score: ${qsofa} ${qsofa>=2?'<strong>(≥2 high risk)</strong>':''}`;
}

/* Initialize open state if page has hash */
(function openHash(){
  if(location.hash){
    const id = location.hash.slice(1);
    const el = document.getElementById(id);
    if(el) el.scrollIntoView({behavior:'smooth', block:'start'});
  }
})();

/* Re-init collapsibles if main content changes */
new MutationObserver(()=> initCollapsibles()).observe(document.getElementById('main'), {childList:true, subtree:true});
</script>

</body>
</html>
